Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

Luca Quartuccio, Martina Fabris, Sara Salvin, Fabiola Atzeni, Marta Saracco, Maurizio Benucci, Marco Cimmino, Pia Morassi, Paola Masolini, Raffaele Pellerito, Maurizio Cutolo, Piercarlo Sarzi-Puttini, Salvatore De Vita

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives. We explored clinical factors associated with a major response to rituximab (RTX) (e.g. ACR 550, and European League against Rheumatism (EULAR) moderate to good response) in patients with active long-standing RA and inadequate response to anti-TNF agents or traditional DMARDs. Methods. RTX was used in 110 RA patients in six different Italian centres. The mean disease activity score on 28 joints (DAS28) was 6.4±0.99 and the mean HAQ was 1.63±0.68 at baseline. Thirty-two patients (29.1%) underwent RTX after the failure of DMARD therapy, 37 (33.6%) had failed or were intolerant to at least two anti-TNF agents, and 41 (37.3%) had failed or were intolerant to one anti-TNF agent. Univariate and multivariate analyses were performed. Results. The number of previous anti-TNF agents (P=0.043), HAQ (P=0.023), RF positivity (P

Original languageEnglish
Pages (from-to)1557-1559
Number of pages3
JournalRheumatology
Volume48
Issue number12
DOIs
Publication statusPublished - 2009

Keywords

  • Anti-CCP
  • Anti-TNF
  • DMARDs
  • Rheumatoid arthritis
  • Rheumatoid factor
  • Rituximab

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this